BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241202
DTEND;VALUE=DATE:20241205
DTSTAMP:20260515T135952
CREATED:20240808T110905Z
LAST-MODIFIED:20240808T110905Z
UID:39544-1733097600-1733356799@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year’s explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. \nThis year’s agenda brings you the opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication. Leading experts including Cartesian Therapeutics\, Bristol Myers Squibb\, the University of Pennsylvania\, ImmPACT Bio and more\, will cover their latest clinical updates\, next-generation candidates\, novel antigen targets\, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease. \nThis is your chance to connect with top cell therapy pioneers\, clinicians\, investors\, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment. \nFind out more here.
URL:http://www.pharmajournalist.com/event/2nd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T135952
CREATED:20240808T111110Z
LAST-MODIFIED:20240808T111110Z
UID:39549-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:6th Cell Therapy Analytical Development Summit
DESCRIPTION:As the field of cell therapy evolves\, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials\, leading to more efficient regulatory approval. \nWhy Attend? \n\nExplore the latest advancements in immunophenotype\, cell-based\, and molecular assays.\nConnect with over 40 industry leaders and experts from companies like Bristol Myers Squibb\, Takeda\, and Kite Pharma to delve into assay matrices\, phase-appropriate development\, and specifications.\nParticipate in discussions on overcoming challenges in product characterization\, assay development\, and scale-up\, sharing innovative technologies and best practices to advance cell therapies.\n\nJoin us to elevate the development of safe and effective autologous and allogeneic cell therapies to new heights! \nDownload the NEW 2024 program
URL:http://www.pharmajournalist.com/event/6th-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T135952
CREATED:20240809T123626Z
LAST-MODIFIED:20240813T083728Z
UID:39561-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:Personalized Vaccine Summit
DESCRIPTION:The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA\, DNA\, peptides\, viral\, dendritic cell and more to share how they are conquering common challenges\, developing novel bioinformatic strategies\, and achieving clinical efficacy. \nThis is the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal – cure cancer! Join the likes of BioNTech\, CureVac\, Imvax\, NousCom\, with our expert speaker faculty of leaders and industry pioneers\, for 3 days of content and 15+ deep dive case studies. \nInterested? Find out more here. https://ter.li/lg5a1h
URL:http://www.pharmajournalist.com/event/personalized-vaccine-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T135952
CREATED:20240919T065329Z
LAST-MODIFIED:20240920T112649Z
UID:39788-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:5th Genome Editing Therapeutics Summit
DESCRIPTION:Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery\, Casgevy marks the first approved gene-editing therapy\, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases\, with a rapidly growing pipeline of precision genome-editing techniques emerging. \n \nThe 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations\, expert panels\, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases\, base and prime editing\, multiplex editing\, and precision tools enabling small and large genome modifications. Additionally\, it will highlight epigenome editing\, recombinase and transposon-based technologies\, and innovative delivery vehicles. \nOver three days\, industry and academic leaders will present the latest research on cutting-edge therapies\, discussing the safety\, precision\, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first\, with a strong focus on creating robust safety profiles\, detecting off-target effects\, and facilitating investigational new drug (IND) filings. \nParticipants will gain actionable insights to improve the precision and safety of their technologies\, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs. \nJoin us and be part of the gene-editing revolution shaping the future of therapeutic development!
URL:http://www.pharmajournalist.com/event/5th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR